Shi-Lei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shi-Lei Liu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ping Dong
Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, China
4 shared publications - Jingwei Zhao
Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
3 shared publications - Li-Jia Pan
Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, China
3 shared publications - Wei Gong
Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, China
3 shared publications - Cheng Zhao
Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, 200092, China; Shanghai Key Laboratory of Biliary Tract Disease Research, No. 1665 Kongjiang Road, Shanghai, 200092, China
2 shared publications - Liu-Qing Shi
Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China; Research Institute of Biliary Tract Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
2 shared publications
Latest Publications
- Open Access
- 28 January 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 1642-1660
Pharmacological Inhibition of APT2 by Solasonine Promotes Ferroptosis Through Palmitoylation Modulation in Gallbladder Cancer
Gallbladder cancer (GBC), the most prevalent and lethal biliary tract malignancy, lacks effective therapeutic strategies. Solasonine (SS), a bioactive steroidal alkaloid derived from Solanum nigrum L, exhibits antitumor activity in multiple cancers, but its role in GBC and association with ferroptosis remains unknown. The purpose of this study is to investigate the therapeutic effects of SS on GBC and its underlying mechanisms using both in vitro and in vivo models. The efficacy was tested in subcutaneous models. Then, the anti‐GBC effects of SS were assessed via CCK‐8, colony formation, and EdU assays. Biosafety was evaluated using L‐2F7 cells and murine serum biomarkers. RNA sequencing identified key pathways, validated by ChIP‐qPCR and dual‐luciferase reporter assays. Ferroptosis induction was confirmed by measuring MDA, GSH, ROS, Fe2+, qRT‐PCR/Western blot (GPX4/SLC7A11), and rescue experiments. Direct binding of SS to APT2 was demonstrated through molecular docking, CETSA, and SPR. The study employed orthotopic xenograft models, transwell assays, and wound healing assays to investigate the effects of SS on the metastasis of GBC. SS triggered ferroptosis in GBC by elevating MDA, ROS, and Fe2+ while depleting GSH and downregulating GPX4/SLC7A11. Mechanistically, SS directly bound APT2, inhibiting its enzymatic activity and blocking STAT3 depalmitoylation. This prevented p‐STAT3 nuclear translocation, suppressing transcription of ferroptosis inhibitors GPX4 and SLC7A11. In vivo, SS suppressed tumor growth by subcutaneous and orthotopic models with no systemic toxicity. Our findings reveal SS as a novel APT2‐targeted ferroptosis inducer that inhibits GBC progression via inhibiting the depalmitoylation process of STAT3, providing a safe and effective therapeutic candidate for this intractable malignancy.
- 28 January 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 1642-1660
Open AccessPharmacological Inhibition of APT2 by Solasonine Promotes Ferroptosis Through Palmitoylation Modulation in Gallbladder Cancer
Gallbladder cancer (GBC), the most prevalent and lethal biliary tract malignancy, lacks effective therapeutic strategies. Solasonine (SS), a bioactive steroidal alkaloid derived from Solanum nigrum L, exhibits antitumor activity in multiple cancers, but its role in GBC and association with ferroptosis remains unknown. The purpose of this study is to investigate the therapeutic effects of SS on GBC and its underlying mechanisms using both in vitro and in vivo models. The efficacy was tested in subcutaneous models. Then, the anti‐GBC effects of SS were assessed via CCK‐8, colony formation, and EdU assays. Biosafety was evaluated using L‐2F7 cells and murine serum biomarkers. RNA sequencing identified key pathways, validated by ChIP‐qPCR and dual‐luciferase reporter assays. Ferroptosis induction was confirmed by measuring MDA, GSH, ROS, Fe2+, qRT‐PCR/Western blot (GPX4/SLC7A11), and rescue experiments. Direct binding of SS to APT2 was demonstrated through molecular docking, CETSA, and SPR. The study employed orthotopic xenograft models, transwell assays, and wound healing assays to investigate the effects of SS on the metastasis of GBC. SS triggered ferroptosis in GBC by elevating MDA, ROS, and Fe2+ while depleting GSH and downregulating GPX4/SLC7A11. Mechanistically, SS directly bound APT2, inhibiting its enzymatic activity and blocking STAT3 depalmitoylation. This prevented p‐STAT3 nuclear translocation, suppressing transcription of ferroptosis inhibitors GPX4 and SLC7A11. In vivo, SS suppressed tumor growth by subcutaneous and orthotopic models with no systemic toxicity. Our findings reveal SS as a novel APT2‐targeted ferroptosis inducer that inhibits GBC progression via inhibiting the depalmitoylation process of STAT3, providing a safe and effective therapeutic candidate for this intractable malignancy.
- Open Access
- 6 April 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 347, 119671
Wu-Mei-Wan promotes ferroptosis in gallbladder cancer through STAT3 negative regulation: An integrated HPLC, proteomics, network pharmacology, and experimental validation study
- 6 April 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 347, 119671
Open AccessWu-Mei-Wan promotes ferroptosis in gallbladder cancer through STAT3 negative regulation: An integrated HPLC, proteomics, network pharmacology, and experimental validation study
- Open Access
- 8 February 2024
- Published by Elsevier in Cancer Letters
- Vol. 587, 216703
NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14
- 8 February 2024
- Published by Elsevier in Cancer Letters
- Vol. 587, 216703
Open AccessNONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14
- Open Access
- 30 September 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-17
Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
Background: Gallbladder cancer (GBC) is a highly aggressive malignant cancer in the biliary system with poor prognosis. XPO1 (chromosome region maintenance 1 or CRM1) mediates the nuclear export of several proteins, mainly tumor suppressors. Thus, XPO1 functions as a pro-oncogenic factor. KPT-330 (Selinexor) is a United States Food and Drug Administration approved selective inhibitor of XPO1 that demonstrates good therapeutic effects in hematologic cancers. However, the function of XPO1 and the effect of KPT-330 have not been reported in GBC. Methods: We analyzed the correlation between XPO1 expression levels by q-PCR and clinical features of GBC patients. Cell proliferation assays were used to analyze the in vitro antitumor effects of XPO1 inhibitor KPT-330. mRNA sequencing was used to explore the underlying mechanisms. Western blot was performed to explore the relationship between apoptosis and autophagy. The in vivo antitumor effect of KPT-330 was investigated in a nude mouse model of gallbladder cancer. Results: We found that high expression of XPO1 was related to poor prognosis of GBC patients. We observed that XPO1 inhibitor KPT-330 inhibited the proliferation of GBC cells in vitro. Furthermore, XPO1 inhibitor KPT-330 induced apoptosis by reducing the mitochondrial membrane potential and triggering autophagy in NOZ and GBC-SD cells. Indeed, XPO1 inhibitor KPT-330 led to nuclear accumulation of p53 and activated the p53/mTOR pathway to regulate autophagy-dependent apoptosis. Importantly, KPT-330 suppressed tumor growth with no obvious toxic effects in vivo. Conclusion: XPO1 may be a promising prognostic indicator for GBC, and KPT-330 appears to be a potential drug for treating GBC effectively and safely.
- 30 September 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-17
Open AccessInhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
Background: Gallbladder cancer (GBC) is a highly aggressive malignant cancer in the biliary system with poor prognosis. XPO1 (chromosome region maintenance 1 or CRM1) mediates the nuclear export of several proteins, mainly tumor suppressors. Thus, XPO1 functions as a pro-oncogenic factor. KPT-330 (Selinexor) is a United States Food and Drug Administration approved selective inhibitor of XPO1 that demonstrates good therapeutic effects in hematologic cancers. However, the function of XPO1 and the effect of KPT-330 have not been reported in GBC. Methods: We analyzed the correlation between XPO1 expression levels by q-PCR and clinical features of GBC patients. Cell proliferation assays were used to analyze the in vitro antitumor effects of XPO1 inhibitor KPT-330. mRNA sequencing was used to explore the underlying mechanisms. Western blot was performed to explore the relationship between apoptosis and autophagy. The in vivo antitumor effect of KPT-330 was investigated in a nude mouse model of gallbladder cancer. Results: We found that high expression of XPO1 was related to poor prognosis of GBC patients. We observed that XPO1 inhibitor KPT-330 inhibited the proliferation of GBC cells in vitro. Furthermore, XPO1 inhibitor KPT-330 induced apoptosis by reducing the mitochondrial membrane potential and triggering autophagy in NOZ and GBC-SD cells. Indeed, XPO1 inhibitor KPT-330 led to nuclear accumulation of p53 and activated the p53/mTOR pathway to regulate autophagy-dependent apoptosis. Importantly, KPT-330 suppressed tumor growth with no obvious toxic effects in vivo. Conclusion: XPO1 may be a promising prognostic indicator for GBC, and KPT-330 appears to be a potential drug for treating GBC effectively and safely.